Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NOVONIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NOVONIX's regulatory disclosures and financial reporting.
NOVONIX Limited reported quarterly operational and cash flow details while progressing its strategic graphite anode active material business. The company delivered a mass-production C-sample of synthetic graphite AAM to Panasonic Energy, with internal testing indicating it meets specifications, and reaffirmed its target to begin mass production for Panasonic in the second half of 2027, subject to completion of qualification. It completed an institutional placement of A$20.7 million and raised A$0.96 million via a share purchase plan, and the U.S. Government certified the Riverside project in connection with a previously allocated US$103 million Section 48C tax credit. NOVONIX also closed the divestiture of its Battery Technology Solutions division.
For the quarter ended 30 June 2026, net cash used in operating activities was 8,642 $USD’000 and investing outflows were 2,441 $USD’000, while financing activities provided 13,226 $USD’000. Cash and cash equivalents were US$59.5 million, with estimated funding capacity of 6.9 quarters. Capital expenditures totaled 2,260 $USD’000, mainly for the Riverside facility, and related-party payments were US$281,000. The company has fully drawn US$40,000,000 in unsecured convertible debentures and a USD$30,100,000 real estate facility.
NOVONIX Ltd director Sharan Burrow reported acquiring 31,250 ordinary shares on 2026-07-22 in an "other" acquisition (transaction code J) at $0.16 per share. Following this transaction, Burrow directly holds 246,989 ordinary shares. The Rule 10b5-1 trading-plan checkbox is not marked.
NOVONIX Limited completed a Share Purchase Plan, issuing 6,016,250 fully paid ordinary shares at A$0.16 each to raise A$962,600 before costs. The offer, which closed on 17 July 2026, allowed eligible shareholders to apply for up to A$30,000 of new shares.
The company plans to use the proceeds to fund capital expenditure to support production capacity and forecast customer demand. Valid applications were received from approximately 89 eligible shareholders, with an average application of approximately A$10,816 and a participation rate of approximately 0.3% of eligible shareholders.
The 6,016,250 new SPP Shares represent approximately 0.6% of NOVONIX’s ordinary shares on issue. Following quotation, total ordinary fully paid shares quoted on ASX are 997,612,994.
NOVONIX Limited reports that the ASX has granted waivers from Listing Rules 7.1 and 10.11 for its Share Purchase Plan. These waivers allow NOVONIX to issue new SPP shares at an offer price of $0.16 per share without prior shareholder approval and without using its standard placement capacity.
The offer price is the same as the institutional placement completed earlier and represents a discount of about 31.2% to the 5-day VWAP calculated to 15 June 2026. The company expects overall dilution from the SPP to be approximately 2.17%, with SPP shares capped at no more than 30% of existing fully paid ordinary shares.
The SPP timetable runs from a record date on 16 June 2026, opens on 22 June 2026, closes on 14 August 2026, with allotment on or about 19 August 2026 and trading of SPP shares expected to commence on or about 20 August 2026.
NOVONIX LIMITED has applied to quote 34,824 additional ordinary fully paid shares on the ASX, issued on July 3, 2026 after performance rights were converted under an employee incentive scheme. These new shares are valued at an estimated AUD 0.155 per security and rank equally with existing shares.
Following this small non-cash issuance, the company’s total quoted ordinary share capital will comprise 991,596,744 NVX ordinary fully paid shares. NOVONIX also has several classes of unquoted securities on issue, including performance rights, options, share rights, convertible notes and convertible debentures.
NOVONIX Ltd Chief Financial Officer Robert Buell Long reported internal changes to his equity awards involving performance rights. On June 30, 2026, three transactions coded as “J” (Other acquisition or disposition) affected a total of 4,576,670 performance rights tied to ordinary shares, all at a reported price of $0.00 per right. Each line shows zero performance rights remaining of that series following the transactions, and no ordinary share purchases or sales were reported.
NOVONIX Limited has detailed the pay package for Ron Edmonds as Interim Chief Financial Officer. His interim term runs for 3–6 months from 1 July 2026.
Mr Edmonds will receive a USD$450,000 base salary, pro‑rated for an expected 75% workload, plus a short‑term incentive of up to 100% of fixed pay based on Board‑set performance targets. He is also eligible for additional Director share rights valued at USD$95,000, subject to shareholder approval.
He remains a director but has stepped aside as Chair while serving as Interim CFO. Deputy Chair Admiral Robert Natter has resumed the role of Chair for the interim period, and the arrangements will continue until a permanent CFO is appointed or his interim role ends earlier.
NOVONIX Limited has launched a Share Purchase Plan (SPP) giving eligible Australian and New Zealand shareholders the option to buy additional shares at a discounted price. The company aims to raise about A$3.0 million through the SPP at an issue price of A$0.16 per share.
Each eligible holder can apply for parcels of up to A$30,000 in new shares without brokerage, with pricing set at a 33.3% discount to the A$0.24 closing price on 15 June 2026 and a 31.2% discount to the five‑day VWAP to that date. The SPP follows an institutional placement that raised approximately A$20.7 million, with combined proceeds earmarked for capital expenditure to expand production capacity and meet forecast customer demand.
Novonix Limited has applied to quote 129,334,163 new ordinary fully paid shares on the ASX. These shares were issued as part of a previously announced placement and are priced at AUD 0.16 per share, with an issue date of June 22, 2026.
After quotation, Novonix will have 991,561,920 ordinary shares on issue. The company also has unquoted instruments on issue, including 27,401,382 performance rights, 14,016,667 options, 1,371,566 share rights, 45,221,586 convertible notes and 35,000,000 convertible debentures, which together outline additional potential equity overhang.
NOVONIX Limited is raising new equity through an institutional placement and a discounted share purchase plan. The company received firm commitments for approximately A$20.7 million via an Institutional Placement of 129,334,163 fully paid ordinary shares at A$0.16 per share, using its remaining 15% placement capacity under ASX Listing Rule 7.1.
In parallel, NOVONIX is launching a Share Purchase Plan (SPP) allowing eligible Australia and New Zealand shareholders to apply for up to A$30,000 of shares each, at the same A$0.16 offer price, with a maximum of 18,750,000 SPP shares and an expected raise of approximately A$3.0 million if fully subscribed.
The offer price represents a 33.3% discount to the last traded price of A$0.24 on 15 June 2026 and a 31.2% discount to the five-day VWAP of A$0.23. Proceeds are expected to fund capital expenditure to expand production capacity and support forecast customer demand. A trading halt was requested on 16 June 2026 ahead of the capital raising announcement.